Market cap of Statera Biopharma Inc. [STAB] reaches 6.54M – now what?

Statera Biopharma Inc. [NASDAQ: STAB] closed the trading session at $0.12 on 11/02/22. The day’s price range saw the stock hit a low of $0.12, while the highest price level was $0.1405. The company report on October 27, 2022 that Statera Biopharma Receives Positive Nasdaq Listing Determination.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Statera Biopharma, Inc. (NASDAQ:STAB) (the “Company” or “Statera Biopharma”), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that, by decision dated October 26, 2022, a Nasdaq Hearings Panel granted the Company’s request for continued listing on The Nasdaq Capital Market (“Nasdaq”), subject to the Company’s satisfaction of certain interim milestones and, ultimately, the Company’s compliance with all applicable criteria for continued listing on Nasdaq, including the $1.00 bid price and $2.5 million stockholders’ equity requirements, by January 31, 2023.

The stocks have a year to date performance of -94.57 percent and weekly performance of -16.19 percent. The stock has been moved at -57.84 percent over the last six months. The stock has performed -4.00 percent around the most recent 30 days and changed -45.74 percent over the most recent 3-months.

If compared to the average trading volume of 2.78M shares, STAB reached to a volume of 3535593 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Statera Biopharma Inc. [STAB]:

The Average True Range (ATR) for Statera Biopharma Inc. is set at 0.03, with the Price to Sales ratio for STAB stock in the period of the last 12 months amounting to 2.62.

STAB stock trade performance evaluation

Statera Biopharma Inc. [STAB] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -16.19. With this latest performance, STAB shares dropped by -4.00% in over the last four-week period, additionally sinking by -57.84% over the last 6 months – not to mention a drop of -96.57% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for STAB stock in for the last two-week period is set at 41.71, with the RSI for the last a single of trading hit 38.57, and the three-weeks RSI is set at 42.79 for Statera Biopharma Inc. [STAB]. The present Moving Average for the last 50 days of trading for this stock 0.1635, while it was recorded at 0.1390 for the last single week of trading, and 0.3885 for the last 200 days.

Statera Biopharma Inc. [STAB]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Statera Biopharma Inc. [STAB] shares currently have an operating margin of -2057.00 and a Gross Margin at +67.16. Statera Biopharma Inc.’s Net Margin is presently recorded at -2346.46.

Statera Biopharma Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.10 and a Current Ratio set at 0.10.

Statera Biopharma Inc. [STAB]: Insider Ownership positions

There are presently around $0 million, or 6.20% of STAB stock, in the hands of institutional investors. The top three institutional holders of STAB stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 1,636,235, which is approximately 851.753% of the company’s market cap and around 17.16% of the total institutional ownership; VANGUARD GROUP INC, holding 389,110 shares of the stock with an approximate value of $49000.0 in STAB stocks shares; and NORTHERN TRUST CORP, currently with $21000.0 in STAB stock with ownership of nearly 0% of the company’s market capitalization.

Positions in Statera Biopharma Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 11 institutional holders increased their position in Statera Biopharma Inc. [NASDAQ:STAB] by around 1,808,863 shares. Additionally, 10 investors decreased positions by around 812,963 shares, while 17 investors held positions by with 515,176 shares. The mentioned changes placed institutional holdings at 3,137,002 shares, according to the latest SEC report filing. STAB stock had 6 new institutional investments in for a total of 213,623 shares, while 5 institutional investors sold positions of 602,704 shares during the same period.

LEAVE A REPLY

Please enter your comment!
Please enter your name here